Table 1.

Performance of the Panbio COVID-19 antigen Rapid Test Device.

Overall	TP	FP	TN	FN	PPA (95% CI)	NPA (95% CI)
NP sample	76	1	519	56	57.3% (48.3–65.8)	99.8% (98.8–100)
Nasal sample	59	0	527	73	44.7% (36.1–53.6)	100% (99.1–100)
Saliva sample	28	0	489	93	23.1% (16.2–31.9)	100% (99–100)
Nasal+saliva	60	0	489	61	49.6% (40.4–58.8)	100% (99–100)
Nasal sample
Symptomatic	51	0	297	46	52.6% (42.2–62.7)	100% (98.4–100)
Ct ≤ 25	43	0	0	12	78% (65–88)
Ct ≤ 30	48	0	0	25	66% (54–76)
Ct ≤ 35	51	0	0	43	54% (44–64)
Asymptomatic	8	0	230	27	22.9% (11–40.6)	100% (98–100)
Ct ≤ 25	8	0	0	5	62% (32–85)
Ct ≤ 30	8	0	0	15	35% (17–57)
Ct ≤ 35	8	0	0	24	25% (0–69)
Saliva sample
Symptomatic	25	0	277	64	28.1% (19.3–38.8)	100% (98.3–100)
Ct ≤ 25	21	0	0	30	41% (28–56)
Ct ≤ 30	25	0	0	42	37% (26–50)
Ct ≤ 35	25	0	0	61	29% (20–40)
Asymptomatic	3	0	212	29	9.4% (2.5–2.6)	100% (97.8–100)
Ct ≤ 25	3	0	0	9	25% (7–57)
Ct ≤ 30	3	0	0	17	15% (4–39)
Ct ≤ 35	3	0	0	26	10% (3–28)
Nasal+saliva
Symptomatic	55	0	277	37	58.4% (47.5–68.6)	100% (98.3–100)
Ct ≤ 25	45	0	0	8	85% (72–93)
Ct ≤ 30	52	0	0	18	74% (62–84)
Ct ≤ 35	55	0	0	34	62% (51–72)
Asymptomatic	9	0	212	24	27.3% (13.9–45.8)	100% (97.8–100)
Ct ≤ 25	9	0	0	4	69% (39–90)
Ct ≤ 30	9	0	0	12	43% (23–66)
Ct ≤ 35	9	0	0	21	30% (0–69)

Unless specified, all analyses have been performed in nasopharyngeal samples. TP, true positive; FP, false positive; TN, true negative; FN, false negative; PPA, positive percent agreement; NPA, negative percent agreement; NP, nasopharyngeal; Ct, cycle threshold of RT-PCR.